Article body
Novo Nordisk shares fell roughly 8% Thursday after Hims & Hers Health (HIMS) said it would offer a low-cost compounded version of Wegovy — Novo's recently launched oral semaglutide obesity pill. Eli Lilly (LLY) also dropped on the news. The dual selloff shows just how sensitive these multibillion-dollar drug franchises have become to pricing pressure from compounding pharmacies and telehealth platforms.
What Hims Is Doing
Hims & Hers is positioning itself as the affordable on-ramp to GLP-1 weight-loss therapy. Its compounded semaglutide offering — a copycat formulation of the active ingredient in both Wegovy and Ozempic — threatens to pull cost-sensitive patients away from brand-name products that can run $1,000 or more per month without insurance.
The expansion into a compounded version of the *oral* Wegovy pill is a notable escalation. Novo Nordisk only recently launched the pill form of semaglutide in the U.S. as a more convenient alternative to its injectable counterpart. Hims moving to undercut the pill this early in its commercial life could blunt a growth catalyst Novo was counting on to extend its GLP-1 runway.
Why NVO Takes the Bigger Hit
Novo's steeper drop reflects its more direct exposure. Wegovy is the company's flagship obesity asset, and the oral semaglutide launch was one of its most anticipated near-term catalysts. With Hims offering a compounded alternative at a fraction of the price, investors are now reassessing how much volume and pricing power Novo can realistically hold onto.
Lilly's Zepbound (tirzepatide) isn't directly targeted by this specific compounded formulation. But the read-through is straightforward: if patients increasingly gravitate toward cheaper compounded GLP-1 options, the entire premium obesity drug category faces a pricing and demand ceiling. Lilly has dealt with compounding threats before, particularly after the FDA declared tirzepatide no longer in shortage, which had previously given compounders legal cover to replicate it.
The Compounding Pharmacy Backstory
FDA rules allow compounding pharmacies to produce copies of branded drugs when those drugs appear on the official shortage list. The GLP-1 shortage era handed compounders and platforms like Hims a legal opening to offer semaglutide and tirzepatide alternatives at steep discounts. Regulators have been tightening those rules as shortages ease, but the legal and commercial landscape remains fluid. Hims has shown a consistent willingness to push the boundaries of what the rules permit.
The company has already built a substantial business around compounded GLP-1s. Thursday's announcement signals it intends to extend that playbook to oral formulations as fast as the market allows.
What Investors Are Watching
For those holding NVO or LLY, a few questions now sit front and center:
- Pricing durability: Can Novo and Lilly maintain premium pricing if compounded alternatives remain consistently available at a fraction of the cost?
- Volume assumptions: Sell-side models for both companies embed significant patient volume ramp assumptions. If a meaningful share of new patients chooses compounded versions instead, consensus revenue estimates may face downward pressure.
- Regulatory wildcards: The FDA's enforcement posture on compounding is the single biggest variable here. A crackdown on compounders could quickly reverse the competitive dynamic, but that outcome depends on policy decisions rather than business fundamentals.
Analysts have, in general, remained constructive on both NVO and LLY over the long term, pointing to the scale of the global obesity epidemic and the clinical differentiation of branded GLP-1s. In the near term, though, the market is clearly repricing the risk that the two companies' premium positioning isn't as durable as previously assumed. That is, in the opinion of market observers tracking the sector, a meaningful shift in sentiment.
HIMS sits on the other side of that trade. Every dollar of market share it captures from brand-name GLP-1s represents incremental revenue for a platform still in growth mode. Whether regulators allow the compounded oral semaglutide offering to stand, or move to shut it down, will likely determine how long that tailwind lasts.